Learning CenterEducational ActivitiesView
Online Course

CARE 2020 MOC Sessions

Date:

Expires Nov 22, 2021
Register Now

Program Information

CME: 12.0     MOC: 12.0

Assess your rheumatology medical knowledge and enhance your patient care. With CARE 2020 MOC Sessions you receive:

  • 36 case-based, multiple-choice questions with in-depth answer rationales, divided into three modules
  • Up to 12.0 AMA PRA Category 1 Credit(s)™ and 12.0 ABIM MOC points with a passing score of 70% or higher (4.0 CME credits / 4.0 MOC points per module)

Target Audience
Rheumatologists, physicians, healthcare providers who care for patients with rheumatic diseases, and those interested or engaged in rheumatology research.

Learning Objectives
Upon completion of this activity, participants should be able to:

CARE 2020 MOC Session 1 - Pregnancy in Rheumatology

  • Understand medication compatibility with pregnancy
  • Review contraception for women with rheumatic disease
  • Manage active lupus in pregnancy
  • Manage inflammatory arthritis in pregnancy

CARE 2020 MOC Session 2 - IgG4 Related Disease and Sjögren’s Syndrome

  • Understand the 2019 ACR/EULAR Classification Criteria for IgG4-RD and their implications for the clinical evaluation of this disease
  • Explore the pearls and pitfalls of using serum IgG4 concentrations to evaluate patients with possible IgG4-RD and to follow those with established diagnoses
  • Review current approaches to treatment in IgG4 Related Disease
  • Recognize and manage the glandular and extraglandular manifestations of Sjögren’s syndrome. Appreciate the genetic and immunologic mechanisms involved in the pathogenesis of Sjögren’s syndrome
  • Understand the strength of the scientific evidence supporting the pharmacological management of Sjögren’s syndrome

CARE 2020 MOC Session 3 - Inflammatory Ocular Disease and Neuro-rheumatology

  • Recognize when a patient with dry eye needs to consult an ophthalmologist
  • Follow current guidelines to minimize ocular toxicity from hydroxychloroquine
  • Identify rheumatic disease in patients with uveitis based on a knowledge as to how rheumatic diseases affect the eye
  • Increase awareness of less commonly recognized clinical manifestations and disease outcomes
  • Understand the role of diagnostic testing in diagnosing disease and determining disease activity
  • Become familiar with treatments used in for neuro-rheumatological conditions
  • Distinguish between neuro-rheumatological disease and their mimickers

Registration Fees

Free for ACR Convergence 2020 attendees.*

*This online activity is intended for ACR Convergence 2020 live attendees only.

CME and MOC Information

Accreditation Statement
The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement
The ACR designates this online activity for a maximum of 12.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities.

MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABIM MOC Badge

Faculty and Disclosures

ACR Disclosure Statement
The ACR is an independent, professional organization that does not endorse specific procedures or products of any pharmaceutical/biotech concern. Educational activities provided by the ACR must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias.

Faculty participating in an ACR-sponsored activity must disclose to the editorial team and audience any financial or other relationship(s) including, but not limited to:

  1. Stock, stock options or bond holdings in a for-profit corporation or self-directed pension plan
  2. Research grants
  3. Employment (full or part-time)
  4. Ownership or partnership
  5. Consulting fees or other remuneration (payment)
  6. Non-remunerative positions of influence such as officer, board member, trustee, or public spokesperson
  7. Receipt of royalties
  8. Speakers' bureau
  9. Other

The faculty reported the following disclosures.

Question Authors

  • Justus Fiechtner, MD - No relevant financial relationships to disclose
  • Prateek Gandiga, MD - No relevant financial relationships to disclose
  • Jennifer Medlin, MD - No relevant financial relationships to disclose
  • Abhishek Nandan, MD - No relevant financial relationships to disclose
  • Jennifer Stichman, MD - No relevant financial relationships to disclose
  • Huzaefah Syed, MD - No relevant financial relationships to disclose

Question Reviewers

  • Meghan Clowse, MD - Exagen Diagnostics2, GlaskSmithKline5, Corbus5, EMD-Serono5, Galapagos5, 9, Pfizer2, UCB5
  • Jeffrey Gelfand, MD - Amgen2 (spouse), Roche/Genentech2, Biogen5 (spouse), Alexion5 (spouse), Theranica5, Impel Neuropharma5, Advanced Clinic5, Biohaven5Satsuma5, UpToDate7 (spouse)
  • James Rosenbaum, MD - AbbVie5 , Corvus5 , Eyevensys5, Gilead5, Horizon2, Novartis5, Pfizer2,Santen5, Roche5, UpToDate7
  • E. William St.Clair, MD - Bristol Myers Squib2, 5
  • John Stone, MD - Roche/Genentech2, 5

Quick Links

Contact Info / Inquiries

education@rheumatology.org
404-633-3777, ext. 381

© 2021 American College of Rheumatology.  All rights reserved.  Website & Privacy Policies | Sitemap | Help | Contact Us